CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts:Part A - first in human ...
Phase 1
Phoenix, Arizona, United States and 14 other locations
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...
Phase 4
Phoenix, Arizona, United States and 32 other locations
A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis...
Phase 3
Phoenix, Arizona, United States and 20 other locations
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early...
Phase 4
Phoenix, Arizona, United States and 35 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Phoenix, Arizona, United States and 208 other locations
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...
Phase 3
Phoenix, Arizona, United States and 225 other locations
The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis...
Phase 2
Scottsdale, Arizona, United States and 70 other locations
for the overall conduct of the study at the site, confirmation of subject eligibility, routine study subject clinical management including for MS...
Phase 3
Phoenix, Arizona, United States and 60 other locations
This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects w...
Phase 2
Phoenix, Arizona, United States and 24 other locations
American (AA) and Hispanic/Latino (HA) patients with relapsing multiple sclerosis (RMS) receiving treatment with Ocrelizumab. The s...
Phase 4
Phoenix, Arizona, United States and 30 other locations
Clinical trials
Research sites
Resources
Legal